Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lu

Showing results (1311-1320 of 1,860) with videos related to

Pageof 186
Sort By:
Cancers|November 9, 2024
Circulating Neoplastic-Immune Hybrid Cells Are Biomarkers of Occult Metastasis and Treatment Response in Pancreatic CancerRanish K Patel, Michael Parappilly, Hannah C Farley, et al.
American Journal of Ophthalmology|March 19, 2026
Swept-Source OCT Angiography Vascular Metrics as Biomarkers for Renal Function in Patients with Diabetes MellitusItika Garg, Margaret Duich, Chibuike Uwakwe, et al.
Journal of Lower Genital Tract Disease|April 12, 2011
Association of elevated E6 oncoprotein with grade of cervical neoplasia using PDZ interaction-mediated precipitation of E6John W Sellors, Johannes G Schweizer, Peter S Lu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2015
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C Zhou, Y L Wu, G Chen, et al.
Neurology|October 27, 2004
PARK6-linked autosomal recessive early-onset parkinsonism in Asian populationsY Hatano, K Sato, B Elibol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2013
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)G Chen, J Feng, C Zhou, et al.
Contemporary Clinical Trials|July 20, 2020
The impact of narratives and active video games on long-term moderate-to-vigorous physical activity: A randomized controlled trial protocolDar Alon, Caio Victor Sousa, Tom Baranowski, et al.
Msystems|February 7, 2018
Abiotic Stresses Shift Belowground <i>Populus</i>-Associated Bacteria Toward a Core Stress MicrobiomeCollin M Timm, Kelsey R Carter, Alyssa A Carrell, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromesYu-Hsiang Chen, Timothy Bi, Minhang Xu, et al.
Blood Cancer Discovery|September 5, 2024
Tracking Rare Single Donor and Recipient Immune and Leukemia Cells after Allogeneic Hematopoietic Cell Transplantation Using Mitochondrial DNA MutationsLivius Penter, Nicoletta Cieri, Katie Maurer, et al.
Pageof 186

Showing results (1311-1320 of 1,860) with videos related to

Sort By:
Pageof 186
Cancers|November 9, 2024
Circulating Neoplastic-Immune Hybrid Cells Are Biomarkers of Occult Metastasis and Treatment Response in Pancreatic CancerRanish K Patel, Michael Parappilly, Hannah C Farley, et al.
American Journal of Ophthalmology|March 19, 2026
Swept-Source OCT Angiography Vascular Metrics as Biomarkers for Renal Function in Patients with Diabetes MellitusItika Garg, Margaret Duich, Chibuike Uwakwe, et al.
Journal of Lower Genital Tract Disease|April 12, 2011
Association of elevated E6 oncoprotein with grade of cervical neoplasia using PDZ interaction-mediated precipitation of E6John W Sellors, Johannes G Schweizer, Peter S Lu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2015
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C Zhou, Y L Wu, G Chen, et al.
Neurology|October 27, 2004
PARK6-linked autosomal recessive early-onset parkinsonism in Asian populationsY Hatano, K Sato, B Elibol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2013
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)G Chen, J Feng, C Zhou, et al.
Contemporary Clinical Trials|July 20, 2020
The impact of narratives and active video games on long-term moderate-to-vigorous physical activity: A randomized controlled trial protocolDar Alon, Caio Victor Sousa, Tom Baranowski, et al.
Msystems|February 7, 2018
Abiotic Stresses Shift Belowground <i>Populus</i>-Associated Bacteria Toward a Core Stress MicrobiomeCollin M Timm, Kelsey R Carter, Alyssa A Carrell, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromesYu-Hsiang Chen, Timothy Bi, Minhang Xu, et al.
Blood Cancer Discovery|September 5, 2024
Tracking Rare Single Donor and Recipient Immune and Leukemia Cells after Allogeneic Hematopoietic Cell Transplantation Using Mitochondrial DNA MutationsLivius Penter, Nicoletta Cieri, Katie Maurer, et al.
Pageof 186